ClinicalTrials.gg
CompletedNCT01069289SUMIREUpdated Oct 25, 2012Results posted

Efficacy and Safety Study of Symbicort® Turbuhaler® Versus Oxis® Turbuhaler® in Chronic Obstructive Pulmonary Disease (COPD) Patients

A Phase 3 interventional study of Budesonide/formoterol (Symbicort Turbuhaler) and Formoterol (Oxis Turbuhaler) in Chronic Obstructive Pulmonary Disease, sponsored by AstraZeneca. Completed at 120 sites in 9 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2012-10-25.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,293
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca — 14 open to participants now, 15 under way, 4 of them phase 3. Pulmonary Disease, Chronic Obstructive · AstraZeneca.

Enrollment
26th of 194
1,293 · median 137
Started
2010
with 24 others
Phase 3
76 of 284
4 open now
Registered
66th of 284
by date

Among the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, this one is the 26th largest by enrollment of the 194 interventional ones that give a count, is one of 25 that started in 2010, is one of 76 in phase 3, and was the 66th registered.

Pulmonary Disease, Chronic Obstructive

5,527 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

14 of the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

Who these studies take

Of the 561 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, or all of them as a file.
02

Study summary

The primary purpose of the study is to investigate if Symbicort is more effective than Oxis in increasing forced expiratory volume in one second (FEV1), measured at the clinics, in patients with COPD.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease

Keywords

  • Symbicort
  • Oxis
  • Chronic Obstructive Pulmonary Disease
  • COPD
  • Efficacy
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A current clinical diagnosis of
  • Documented Chronic Obstructive Pulmonary Disease symptoms for more than 2 years
  • A smoking history of at least 10 pack years

Exclusion criteria

Exclusion Criteria:

  • History and/or current clinical diagnosis of asthma
  • History and/or current clinical diagnosis of atopic diseases such as allergic rhinitis
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,293 participants (actual)

Study arms

  • Experimental
    1

    Symbicort Turbuhaler 160/4.5 microgram, 2 inhalations twice daily

    Drug: Budesonide/formoterol (Symbicort Turbuhaler)

  • Active comparator
    2

    Oxis Turbuhaler 4.5 microgram, 2 inhalations twice daily

    Drug: Formoterol (Oxis Turbuhaler)

Interventions

06

What researchers measure

Primary outcomes

  1. Pre-dose Forced Expiratory Volume in One Second (FEV1)

    The ratio, expressed as percentage, of the geometric mean of available data for Weeks 0, 4, 8 and 12 to the baseline for each treatment group

    Time frame: Before randomization, 0, 4, 8 and 12 weeks after randomization

Secondary outcomes

  1. 1 Hour Post Dose Forced Expiratory Volume in One Second (FEV1)

    The ratio, expressed as percentage, of the geometric mean of available data for Weeks 0, 4, 8 and 12 to the baseline for each treatment group

    Time frame: Before randomization, 0, 4, 8 and 12 weeks after randomization

  2. Pre-dose Forced Vital Capacity (FVC)

    The ratio, expressed as percentage, of the geometric mean of available data for Weeks 0, 4, 8 and 12 to the baseline for each treatment group

    Time frame: Before randomization, 0, 4, 8 and 12 weeks after randomization

  3. 1 Hour Post-dose Forced Vital Capacity (FVC)

    The ratio, expressed as percentage, of the geometric mean of available data for Weeks 0, 4, 8 and 12 to the baseline for each treatment group

    Time frame: Before randomization, 0, 4, 8 and 12 weeks after randomization

  4. Percentage of Participants With Exacerbations

    A Chronic Obstructive Pulmonary Disease (COPD) exacerbation was defined as worsening in COPD symptoms requiring treatment with either a course of systemic steroid or hospitalisation. The percentage of participants who had experienced COPD exacerbation at the end of the study for each treatment group.

    Time frame: Daily during 12-week randomization treatment

  5. Number of Chronic Obstructive Pulmonary Disease (COPD) Exacerbation

    A Chronic Obstructive Pulmonary Disease (COPD) exacerbation was defined as worsening in COPD symptoms requiring treatment with either a course of systemic steroid or hospitalisation. Number of COPD exacerbation during 12-week randomization treatment

    Time frame: Daily during 12-week randomization treatment

  6. Morning Peak Expiratory Flow(PEF)

    The change from Run-in period average to Treatment period average for each treatment group

    Time frame: Daily during run-in period and daily during 12-week randomization treatment

  7. Evening Peak Expiratory Flow (PEF)

    The change from Run-in period average to Treatment period average for each treatment group

    Time frame: Daily during run-in period and daily during 12-week randomization treatment

  8. Total Number of Day With Exacerbation

    Total number of days with COPD exacerbation for each treatment group

    Time frame: Daily during 12-week randomization treatment

  9. Morning Forced Expiratory Volume in One Second (FEV1)

    The change from Run-in period average to Treatment period average for each treatment group

    Time frame: Daily during run-in period and daily during 12-week randomization treatment

  10. Evening Forced Expiratory Volume in One Second (FEV1)

    The change from Run-in period average to Treatment period average for each treatment group

    Time frame: Daily during run-in period and daily during 12-week randomization treatment

  11. Night-time Awakening Due to Chronic Obstructive Pulmonary Disease (COPD) Symptoms

    Scored 0 to 1 (0 = no awakening and 1 = awakening). The change from Run-in period average to Treatment period average for each treatment group

    Time frame: Daily during run-in period and daily during 12-week randomization treatment

  12. Breathlessness Due to Chronic Obstructive Pulmonary Disease (COPD) Symptoms

    There are 5 alternatives (scored 0 to 4, with 4 being the most severe condition). The change from Run-in period average to Treatment period average for each treatment group

    Time frame: Daily during run-in period and daily during 12-week randomization treatment

  13. Cough Due to Chronic Obstructive Pulmonary Disease (COPD) Symptoms

    There are 5 alternatives (scored 0 to 4, with 4 being the most severe condition). The change from Run-in period average to Treatment period average for each treatment group

    Time frame: Daily during run-in period and daily during 12-week randomization treatment

  14. Total Chronic Obstructive Pulmonary Disease (COPD) Symptom Score

    The Total COPD Symptom score is the sum of the measures night-time awakening, breathlessness and cough, ranges from 0 to 12 with 12 being the most severe. The change from Run-in period average to Treatment period average for each treatment group.

    Time frame: Daily during run-in period and daily during 12-week randomization treatment

  15. Use of Rescue Medication

    The change from Run-in period average to Treatment period average for each treatment group.

    Time frame: Daily during run-in period and daily during 12-week randomization treatment

  16. St George's Respiratory Questionnaire (SGRQ) Total Score

    The change from Run-in period average to Treatment period average for each treatment group. The SGRQ ranges from 0 (no impairment of quality of life) to 100 (highest impairment of quality of life).

    Time frame: Daily during run-in period and daily during 12-week randomization treatment

07

Results

Posted Oct 25, 2012

Participant flow

The first participant entered the study on 28 January 2010, and the last participant completed the study on 30 March 2011. A total of 1,710 participants were enrolled at 163 centres in 9 countries in Asia and Europe, and 1,293 participants who fulfilled the randomisation criteria were randomised.

Participant flow — Overall Study
MilestoneSymbicort Turbuhaler (Experimental)Oxis Turbuhaler (Active Comparator)
Started636657
Completed594601
Not completed4256
Withdrew: Withdrawal by subject1526
Withdrew: Adverse event2128
Withdrew: Eligibility criteria not fulfilled20
Withdrew: Severe non-compliance to protocol32
Withdrew: Due to deteriorating health condition10

Outcome measures

PrimaryPre-dose Forced Expiratory Volume in One Second (FEV1)

The ratio, expressed as percentage, of the geometric mean of available data for Weeks 0, 4, 8 and 12 to the baseline for each treatment group

Time frame:
Before randomization, 0, 4, 8 and 12 weeks after randomization
Reported as:
Geometric mean · percentage of Baseline
Pre-dose Forced Expiratory Volume in One Second (FEV1)
percentage of BaselineSymbicort Turbuhaler (Experimental)Oxis Turbuhaler (Active Comparator)
Pre-dose Forced Expiratory Volume in One Second (FEV1)104.6 (37.4 to 311.1)101.5 (35.1 to 218.5)
Secondary1 Hour Post Dose Forced Expiratory Volume in One Second (FEV1)

The ratio, expressed as percentage, of the geometric mean of available data for Weeks 0, 4, 8 and 12 to the baseline for each treatment group

Time frame:
Before randomization, 0, 4, 8 and 12 weeks after randomization
Reported as:
Geometric mean · percentage of Baseline
1 Hour Post Dose Forced Expiratory Volume in One Second (FEV1)
percentage of BaselineSymbicort Turbuhaler (Experimental)Oxis Turbuhaler (Active Comparator)
1 Hour Post Dose Forced Expiratory Volume in One Second (FEV1)113.9 (55.5 to 336.3)111.2 (51.3 to 203.3)
SecondaryPre-dose Forced Vital Capacity (FVC)

The ratio, expressed as percentage, of the geometric mean of available data for Weeks 0, 4, 8 and 12 to the baseline for each treatment group

Time frame:
Before randomization, 0, 4, 8 and 12 weeks after randomization
Reported as:
Geometric mean · percentage of Baseline
Pre-dose Forced Vital Capacity (FVC)
percentage of BaselineSymbicort Turbuhaler (Experimental)Oxis Turbuhaler (Active Comparator)
Pre-dose Forced Vital Capacity (FVC)102.2 (57.3 to 313.8)100.9 (61.5 to 347.6)
Secondary1 Hour Post-dose Forced Vital Capacity (FVC)

The ratio, expressed as percentage, of the geometric mean of available data for Weeks 0, 4, 8 and 12 to the baseline for each treatment group

Time frame:
Before randomization, 0, 4, 8 and 12 weeks after randomization
Reported as:
Geometric mean · percentage of Baseline
1 Hour Post-dose Forced Vital Capacity (FVC)
percentage of BaselineSymbicort Turbuhaler (Experimental)Oxis Turbuhaler (Active Comparator)
1 Hour Post-dose Forced Vital Capacity (FVC)110.1 (62.0 to 262.7)108.7 (63.5 to 272.7)
SecondaryPercentage of Participants With Exacerbations

A Chronic Obstructive Pulmonary Disease (COPD) exacerbation was defined as worsening in COPD symptoms requiring treatment with either a course of systemic steroid or hospitalisation. The percentage of participants who had experienced COPD exacerbation at the end of the study for each treatment group.

Time frame:
Daily during 12-week randomization treatment
Reported as:
Number · percentage of participants
Percentage of Participants With Exacerbations
percentage of participantsSymbicort Turbuhaler (Experimental)Oxis Turbuhaler (Active Comparator)
Percentage of Participants With Exacerbations11.916.9
SecondaryNumber of Chronic Obstructive Pulmonary Disease (COPD) Exacerbation

A Chronic Obstructive Pulmonary Disease (COPD) exacerbation was defined as worsening in COPD symptoms requiring treatment with either a course of systemic steroid or hospitalisation. Number of COPD exacerbation during 12-week randomization treatment

Time frame:
Daily during 12-week randomization treatment
Reported as:
Number · event
Number of Chronic Obstructive Pulmonary Disease (COPD) Exacerbation
eventSymbicort Turbuhaler (Experimental)Oxis Turbuhaler (Active Comparator)
Number of Chronic Obstructive Pulmonary Disease (COPD) Exacerbation93151
SecondaryMorning Peak Expiratory Flow(PEF)

The change from Run-in period average to Treatment period average for each treatment group

Time frame:
Daily during run-in period and daily during 12-week randomization treatment
Reported as:
Mean · Liter/minute (L/min)
Morning Peak Expiratory Flow(PEF)
Liter/minute (L/min)Symbicort Turbuhaler (Experimental)Oxis Turbuhaler (Active Comparator)
Morning Peak Expiratory Flow(PEF)4.29 ± 36.58-4.78 ± 30.61
SecondaryEvening Peak Expiratory Flow (PEF)

The change from Run-in period average to Treatment period average for each treatment group

Time frame:
Daily during run-in period and daily during 12-week randomization treatment
Reported as:
Mean · Liter/minute (L/min)
Evening Peak Expiratory Flow (PEF)
Liter/minute (L/min)Symbicort Turbuhaler (Experimental)Oxis Turbuhaler (Active Comparator)
Evening Peak Expiratory Flow (PEF)2.55 ± 36.57-5.13 ± 31.52
SecondaryTotal Number of Day With Exacerbation

Total number of days with COPD exacerbation for each treatment group

Time frame:
Daily during 12-week randomization treatment
Reported as:
Number · days
Total Number of Day With Exacerbation
daysSymbicort Turbuhaler (Experimental)Oxis Turbuhaler (Active Comparator)
Total Number of Day With Exacerbation6531098
SecondaryMorning Forced Expiratory Volume in One Second (FEV1)

The change from Run-in period average to Treatment period average for each treatment group

Time frame:
Daily during run-in period and daily during 12-week randomization treatment
Reported as:
Mean · Liter (L)
Morning Forced Expiratory Volume in One Second (FEV1)
Liter (L)Symbicort Turbuhaler (Experimental)Oxis Turbuhaler (Active Comparator)
Morning Forced Expiratory Volume in One Second (FEV1)0.0244 ± 0.2136-0.0312 ± 0.1712
SecondaryEvening Forced Expiratory Volume in One Second (FEV1)

The change from Run-in period average to Treatment period average for each treatment group

Time frame:
Daily during run-in period and daily during 12-week randomization treatment
Reported as:
Mean · Liter (L)
Evening Forced Expiratory Volume in One Second (FEV1)
Liter (L)Symbicort Turbuhaler (Experimental)Oxis Turbuhaler (Active Comparator)
Evening Forced Expiratory Volume in One Second (FEV1)0.0176 ± 0.2268-0.0324 ± 0.1724
SecondaryNight-time Awakening Due to Chronic Obstructive Pulmonary Disease (COPD) Symptoms

Scored 0 to 1 (0 = no awakening and 1 = awakening). The change from Run-in period average to Treatment period average for each treatment group

Time frame:
Daily during run-in period and daily during 12-week randomization treatment
Reported as:
Mean · Nights with symptoms
Night-time Awakening Due to Chronic Obstructive Pulmonary Disease (COPD) Symptoms
Nights with symptomsSymbicort Turbuhaler (Experimental)Oxis Turbuhaler (Active Comparator)
Night-time Awakening Due to Chronic Obstructive Pulmonary Disease (COPD) Symptoms-0.20 ± 0.67-0.15 ± 0.66
SecondaryBreathlessness Due to Chronic Obstructive Pulmonary Disease (COPD) Symptoms

There are 5 alternatives (scored 0 to 4, with 4 being the most severe condition). The change from Run-in period average to Treatment period average for each treatment group

Time frame:
Daily during run-in period and daily during 12-week randomization treatment
Reported as:
Mean · units on a scale
Breathlessness Due to Chronic Obstructive Pulmonary Disease (COPD) Symptoms
units on a scaleSymbicort Turbuhaler (Experimental)Oxis Turbuhaler (Active Comparator)
Breathlessness Due to Chronic Obstructive Pulmonary Disease (COPD) Symptoms-0.34 ± 0.66-0.23 ± 0.65
SecondaryCough Due to Chronic Obstructive Pulmonary Disease (COPD) Symptoms

There are 5 alternatives (scored 0 to 4, with 4 being the most severe condition). The change from Run-in period average to Treatment period average for each treatment group

Time frame:
Daily during run-in period and daily during 12-week randomization treatment
Reported as:
Mean · units on a scale
Cough Due to Chronic Obstructive Pulmonary Disease (COPD) Symptoms
units on a scaleSymbicort Turbuhaler (Experimental)Oxis Turbuhaler (Active Comparator)
Cough Due to Chronic Obstructive Pulmonary Disease (COPD) Symptoms-0.24 ± 0.70-0.24 ± 0.68
SecondaryTotal Chronic Obstructive Pulmonary Disease (COPD) Symptom Score

The Total COPD Symptom score is the sum of the measures night-time awakening, breathlessness and cough, ranges from 0 to 12 with 12 being the most severe. The change from Run-in period average to Treatment period average for each treatment group.

Time frame:
Daily during run-in period and daily during 12-week randomization treatment
Reported as:
Mean · units on a scale
Total Chronic Obstructive Pulmonary Disease (COPD) Symptom Score
units on a scaleSymbicort Turbuhaler (Experimental)Oxis Turbuhaler (Active Comparator)
Total Chronic Obstructive Pulmonary Disease (COPD) Symptom Score-0.78 ± 1.62-0.61 ± 1.56
SecondaryUse of Rescue Medication

The change from Run-in period average to Treatment period average for each treatment group.

Time frame:
Daily during run-in period and daily during 12-week randomization treatment
Reported as:
Mean · inhalations/day
Use of Rescue Medication
inhalations/daySymbicort Turbuhaler (Experimental)Oxis Turbuhaler (Active Comparator)
Use of Rescue Medication-0.51 ± 1.51-0.26 ± 1.49
SecondarySt George's Respiratory Questionnaire (SGRQ) Total Score

The change from Run-in period average to Treatment period average for each treatment group. The SGRQ ranges from 0 (no impairment of quality of life) to 100 (highest impairment of quality of life).

Time frame:
Daily during run-in period and daily during 12-week randomization treatment
Reported as:
Mean · units on a scale
St George's Respiratory Questionnaire (SGRQ) Total Score
units on a scaleSymbicort Turbuhaler (Experimental)Oxis Turbuhaler (Active Comparator)
St George's Respiratory Questionnaire (SGRQ) Total Score-4.37 ± 14.544-2.90 ± 13.783

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Symbicort Turbuhaler (Experimental)—43/636 (6.8%)61/636 (9.6%)
Oxis Turbuhaler (Active Comparator)—45/657 (6.8%)66/657 (10%)
Most frequent serious events
Showing 10 of 41
Most frequent serious events
EventSymbicort Turbuhaler (Experimental)Oxis Turbuhaler (Active Comparator)
CHRONIC OBSTRUCTIVE PULMONARY DISEASERespiratory, thoracic and mediastinal disorders24/63628/657
PNEUMONIARespiratory, thoracic and mediastinal disorders3/6361/657
INFECTIVE EXACERBATION OF CHRONIC OBSTRUCTIVE AIRWAYS DISEASERespiratory, thoracic and mediastinal disorders1/6363/657
APPENDICITISInfections and infestations2/6360/657
PNEUMOTHORAXRespiratory, thoracic and mediastinal disorders1/6362/657
ACUTE RESPIRATORY FAILURERespiratory, thoracic and mediastinal disorders1/6360/657
PNEUMONIA BACTERIALInfections and infestations1/6361/657
BRONCHOPNEUMONIAInfections and infestations1/6360/657
POSTOPERATIVE ABSCESSInfections and infestations1/6360/657
ILEUSGastrointestinal disorders1/6360/657
Most frequent other events
Most frequent other events
EventSymbicort Turbuhaler (Experimental)Oxis Turbuhaler (Active Comparator)
NasopharyngitisInfections and infestations35/63632/657
Chronic Obstructive Pulmonary DiseaseRespiratory, thoracic and mediastinal disorders29/63636/657

Baseline characteristics

Age Continuous
Age Continuous(Years)Symbicort Turbuhaler (Experimental)Oxis Turbuhaler (Active Comparator)Total
Mean64.5 (40 to 89)65.6 (40 to 87)65.1 (40 to 89)
Sex: Female, Male
Sex: Female, Male(Participants)Symbicort Turbuhaler (Experimental)Oxis Turbuhaler (Active Comparator)Total
Female7964143
Male5575931150
08

Study locations

120 sites
  • Research Site
    New Delhi, Delhi, India
  • Research Site
    Bangalore, Karnataka, India
  • Research Site
    Mysore, Karnataka, India
  • Research Site
    Trivandrum, Kerala, India
  • Research Site
    Indore, Madhya Pradesh, India
  • Research Site
    Nagpur, Maharashtra, India
  • Research Site
    Coimbatore, Tamil Nadu, India
  • Research Site
    Nagoya, Aichi, Japan
  • Research Site
    Okazaki, Aichi, Japan
  • Research Site
    Seto, Aichi, Japan
  • Research Site
    Toyota-shi, Aichi, Japan
  • Research Site
    Toyota, Aichi, Japan
  • Research Site
    Akita-shi, Akita, Japan
  • Research Site
    Yanagawa, Fukuoka, Japan
  • Research Site
    Takayama-shi, Gifu, Japan
  • Research Site
    Maebashi, Gunma, Japan
  • Research Site
    OTA, Gunma, Japan
  • Research Site
    Hiroshima-shi, Hiroshima, Japan
  • Research Site
    Asahikawa, Hokkaido, Japan
  • Research Site
    Obihiro, Hokkaido, Japan
  • Research Site
    Sapporo, Hokkaido, Japan
  • Research Site
    Tomakomai, Hokkaido, Japan
  • Research Site
    Himeji, Hyogo, Japan
  • Research Site
    Itami, Hyogo, Japan
  • Research Site
    Kobe, Hyogo, Japan
  • Research Site
    Naka-gun, Ibaragi, Japan
  • Research Site
    Hitachi, Ibaraki, Japan
  • Research Site
    Tsukuba, Ibaraki, Japan
  • Research Site
    Kanazawa, Ishikawa, Japan
  • Research Site
    Sakaide, Kagawa, Japan
  • Research Site
    Kagoshima-shi, Kagoshima, Japan
  • Research Site
    Fujisawa, Kanagawa, Japan
  • Research Site
    Kawasaki-shi, Kanagawa, Japan
  • Research Site
    Yokohama-shi, Kanagawa, Japan
  • Research Site
    Yokohama, Kanagawa, Japan
  • Research Site
    Zama-shi, Kanagawa, Japan
  • Research Site
    Matsusaka-shi, MIE, Japan
  • Research Site
    Sendai, Miyagi, Japan
  • Research Site
    Shibata, Miyagi, Japan
  • Research Site
    Chino-shi, Nagano, Japan
  • Research Site
    Matsumoto, Nagano, Japan
  • Research Site
    Isahaya-shi, Nagasaki, Japan
  • Research Site
    Nagaoka, Niigata, Japan
  • Research Site
    Saiki-shi, Oita, Japan
  • Research Site
    Yufu-shi, Oita, Japan
  • Research Site
    Kurashiki-shi, Okayama, Japan
  • Research Site
    Okayama-shi, Okayama, Japan
  • Research Site
    Urasoe-shi, Okinawa, Japan
  • Research Site
    Izumi-shi, Osaka, Japan
  • Research Site
    Kishiwada, Osaka, Japan
  • Research Site
    Moriguchi, Osaka, Japan
  • Research Site
    Osaka-shi, Osaka, Japan
  • Researche Site
    Sakai-shi, Osaka, Japan
  • Research Site
    Kitakatsushika-gun, Saitama, Japan
  • Research Site
    Koshigaya-shi, Saitama, Japan
  • Research Site
    Matsue, Shimane, Japan
  • Research Site
    Chuo, Tokyo, Japan
  • Research Site
    Itabashi-ku, Tokyo, Japan
  • Research Site
    Meguro, Tokyo, Japan
  • Research Site
    Minato-ku, Tokyo, Japan
  • Research Site
    Setagaya, Tokyo, Japan
  • Research Site
    Shinagawa-ku, Tokyo, Japan
  • Research Site
    Suginami-ku, Tokyo, Japan
  • Research Site
    Sumida-ku, Tokyo, Japan
  • Research Site
    Fukuoka, Japan
  • Research Site
    Gifu, Japan
  • Research Site
    Kochi, Japan
  • Research Site
    Kyoto, Japan
  • Research Site
    Saga, Japan
  • Research Site
    Wakayama, Japan
  • Research Site
    Ansan, Korea, Republic of
  • Research Site
    Incheon, Korea, Republic of
  • Research Site
    Seoul, Korea, Republic of
  • Researche Site
    San Fernando, Pampanga, Philippines
  • Research Site
    Davao City, Philippines
  • Research Site
    Iloilo City, Philippines
  • Research Site
    Lipa City, Batangas, Philippines
  • Research Site
    Olongapo City, Philippines
  • Research Site
    Quezon City, Philippines
  • Research Site
    Bialystok, Poland
  • Research Site
    Bydgoszcz, Poland
  • Research Site
    Chodziez, Poland
  • Research Site
    Jaroslaw, Poland
  • Research Site
    Karpacz, Poland
  • Research Site
    Krakow, Poland
  • Research Site
    Lodz, Poland
  • Research Site
    Loma, Poland
  • Research Site
    Lublin, Poland
  • Research Site
    Ostrow Wielkopolski, Poland
  • Research Site
    Pila, Poland
  • Research Site
    Poznan, Poland
  • Research Site
    Ruda Slaska, Poland
  • Research Site
    Slupca, Poland
  • Research Site
    Tczew, Poland
  • Research Site
    Torun, Poland
  • Research Site
    Turek, Poland
  • Research Site
    Wloszczowa, Poland
  • Research Site
    Zabrze, Poland
  • Research Site
    Zawadzkie, Poland
  • Research Site
    Znin, Poland

Showing the first 100 of 120 sites across 9 countries. Choose a country and city above to see the rest.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2010, a primary completion of Mar 2011 and a completion of Mar 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2012, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2010
First posted
Feb 17, 2010
Start
Jan 2010
Primary completionActual
Mar 2011
CompletionActual
Mar 2011
Results first posted
Oct 25, 2012
Last update
Oct 25, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 25, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01069289
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Feb 17, 2010
Start date
Jan 2010
Primary completion
Mar 2011
Completion
Mar 2011
Results posted
Oct 25, 2012
Last update
Oct 25, 2012

Study contacts

Lars-Göran Carlsson, MD
study chair · AstraZeneca R&D, Lund, Sweden
Yoshinosuke Fukuchi, M.D., PhD
principal investigator · Department of Respiratory medicine, Juntendo University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Budesonide/Formoterol Fumarate Dihydrate Inhalation Aerosol

Start the discussion